Effects of SCH27899 (Ziracin), an oligosaccharide everninomicin antibiotic, on urate kinetics in humans

European Journal of Clinical Pharmacology

Volumn 60, Issue 4, 2004, Pages 255-264

  Nagashima, Satoru ^a,b   Niwa, Masayuki ^c   Nishiki, Katsuyuki ^d   Hosoya, Tatsuo ^e   Hishida, Akira ^a   Uematsu, Toshihiko ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Shitoro Clinic   (Japan)

^c GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Clinical Development Department   (Japan)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Oligosaccharide everninomicin antibiotic; SCH27899; Urate kinetics

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; BILIRUBIN; CARBON 14; EVERNIMICIN; LOSARTAN; OLIGOSACCHARIDE; PROBENECID; URATE; VANCOMYCIN;

ANIMAL TISSUE; ARTICLE; BILIRUBIN BLOOD LEVEL; BRUSH BORDER VESICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INFUSION; DRUG MECHANISM; DRUG URINE LEVEL; EXPERIMENT; HEMOCONCENTRATION; HUMAN; HUMAN EXPERIMENT; HYPERURICOSURIA; IN VITRO STUDY; INHIBITION KINETICS; KIDNEY TUBULE EPITHELIUM; KINETICS; MALE; NONHUMAN; NORMAL HUMAN; PH; PRIORITY JOURNAL; RAT; TRANSPORT KINETICS;

EID: 3142694894     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0755-y     Document Type: Article

References (27)

1. Ganguly AK (2000) Ziracin, a novel oligosaccharide antibiotic. J Antibiot (Tokyo) 53:1038-1044
2. Kozawa O, Uematsu T, Matsuno H, Niwa M, Kohno K, Kawato A, Takahashi K, Nagashima S Kanamaru M (2001) Pharmacokinetics of a new parenteral oligosaccharide antibiotic, SCH27899 (Ziracin), in healthy subjects. Antimicrob Agents Chemother 45:917-921
3. Jones RN, Low DE, Pfaller MA (1999) Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn Microbiol Infect Dis 33:101-112
4. Nakashima M, Uematsu T, Kosuge K, Kanamaru M (1992) Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 42:333-335
5. Tsunoda K, Abe K, Hagino T, Omata K, Misawa S, Imai Y, Yoshinaga K (1993) Hypotensive effect of losartan, a non-peptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 6:28-32
6. Kanamaru M, Uematsu T, Nagashima S, Mizuno A, Terakawa M, Sugiyama A, Nakashima M (1993) Aldose reductase inhibitory and uricosuric activities of FK366 in healthy volunteers. J Clin Pharmacol 33:1122-1131
7. Kahn AM, Branham S, Weinman EJ (1983) Mechanism of urate and p-aminohippurate transport in rat renal microvillus membrane vesicles. Am J Physiol 245:F151-F158
8. Roch-Ramel F, Werner D, Guisan B (1994) Urate transport in brush-border membrane of human kidney. Am J Physiol 266:F797-F805
9. Bergwerk AJ, Shi X, Ford AC, Kanai N, Jacquemin E, Burk RD, Bai S, Novikoff PM, Stieger B, Meier PJ, Schuster VL Wolkoff AW (1996) Immunologic distribution of an organic anion transport protein in rat liver and kidney. Am J Physiol 271:G231-G238
10. Leal-Pinto E, Tao W, Rappaport J, Richardson M, Knorr BA, Abramson RG (1997) Molecular cloning and functional reconstitution of a urate transporter/channel. J Biol Chem 272:617-625
11. Edwards RM, Trizna W, Stack EJ, Weinstock J (1996) Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes. J Pharmacol Exp Ther 276:125-129
12. Shah SV, Kempson SA, Northrup TE, Dousa TP (1979) Renal adaptation to a low phosphate diet in rats. J Clin Invest 64:955-966
13. Blomstedt JW, Aronson PS (1980) pH gradient-stimulated transport of urate and p-aminohippurate in dog renal microvillus membrane vesicles. J Clin Invest 65:931-934
14. Kahn AM, Weinman EJ (1985) Urate transport in the proximal tubule: in vivo and vesicle studies. Am J Physiol 249:F789-F798
15. Uematsu T, Nakashima M (1994) Pharmacokinetic and pharmacodynamic properties of a novel xanthine oxidase inhibitor, BOF-4272, in healthy volunteers. J Pharmacol Exp Ther 270:453-459
16. Shahinfar S, Simpson RL, Carides AD, Thiyagarajan B, Nakagawa Y, Umans JG, Parks JH, Coe FL (1999) Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 56:1879-1885
17. Soffer BA, Wright JT Jr, Pratt JH, Wiens B, Goldberg AI, Sweet CS (1995) Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 26:112-117
18. Cui Y, Konig J, Leier I, Buchholz U, Keppler D (2001) Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276:9626-9690
19. Jacquemin E, Hagenbuch B, Stieger B, Wolkoff AW, Meier PJ (1994) Expression cloning of a rat liver Na(+)-independent organic anion transporter. Proc Natl Acad Sci U S A 91:133-137
20. Mueller EA, Kovarik JM, Uresin Y, Preisig-Fluckiger SS, Hensel S, Lucker PW, Holt B (1997) Optimizing the absorption of valspodar, a P-glycoprotein modulator. Part I: selecting an oral formulation and exploring its clinical pharmacokinetics/dynamics. J Clin Pharmacol 37:1001-1008
21. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F (1991) In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51:4226-4233
22. Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Schellens JH, van Tellingen O (2000) Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res 6:4416-4421
23. Stewart A, Steiner J, Mellows G, Laguda B, Norris D, Bevan P (2000) Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 6:4186-4191
24. van Zuylen L, Sparreboom A, van der Gaast A, van der Burg ME, van Beurden V, Bol CJ, Woestenborghs R, Palmer PA, Verweij J (2000) The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin Cancer Res 6:1365-1371
25. Perl TM (1999) The threat of vancomycin resistance. Am J Med 106:826-837
26. Rotchafer JC, Crossley K, Zaske DE, Mead K, Sawchuk RJ, Solem LD (1982) Pharmacokinetics of vancomycin: observation in 28 patients and dosage recommendation. Antimicrob Agents Chemother 22:391-394
27. Jones RN, Marshall SA, Erwin ME (1999) Antimicrobialactivity and spectrum of SCH27899 (Ziracin) tested against gram-positive species including recommendations for routine susceptibility testing methods and quality control. Diagn Microbiol Infect Dis 34:103-110